this post was submitted on 11 Aug 2023
565 points (94.3% liked)

Asklemmy

44152 readers
1402 users here now

A loosely moderated place to ask open-ended questions

Search asklemmy 🔍

If your post meets the following criteria, it's welcome here!

  1. Open-ended question
  2. Not offensive: at this point, we do not have the bandwidth to moderate overtly political discussions. Assume best intent and be excellent to each other.
  3. Not regarding using or support for Lemmy: context, see the list of support communities and tools for finding communities below
  4. Not ad nauseam inducing: please make sure it is a question that would be new to most members
  5. An actual topic of discussion

Looking for support?

Looking for a community?

~Icon~ ~by~ ~@Double_[email protected]~

founded 5 years ago
MODERATORS
 

Most of the time when people say they have an unpopular opinion, it turns out it's actually pretty popular.

Do you have some that's really unpopular and most likely will get you downvoted?

you are viewing a single comment's thread
view the rest of the comments
[–] [email protected] 1 points 1 year ago

Yeah with pharma in particular you need that initial profitability, as you say.

Additionally...

People will say “what would give someone the incentive to make new things?” Without actually thinking it through. For a great example of how lack of IP is a good thing, look at how Shenzhen went from a fishing village to a Chinese San Francisco in a few short decades… one company will take the product of another and iterate on top of it.

This doesn't really make sense. Shenzen company's might have copied products developed by other companies, but surely you still need another company to invest the R & D initially in order to have something to copy.

Consumer products don't "evolve". Developing and producing are two different processes. If there's no IP then there's only an incentive to produce things, and no incentive to develop them. I think this is especially true of pharmaceuticals given that there's no incremental / evolutionary pathway to discovering new drugs and the costs of conducting trials et cetera is preclusive.